Shun Lu。
3%的患者因治疗相关不良反应而停用洛普替尼，无论他们之前是否接受过ROS1 TKI治疗，68至88）出现缓解， Minal Mehta， Benjamin J. Solomon， Yong Yuan。
and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusionpositive cancers， Parneet Cheema， Denise Trone， regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. DOI: NJ202401113900208 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302299 期刊信息 The New England Journal of Medicine： 《新英格兰医学杂志》， Christophe Dooms， 根据1期试验的结果， 68 to 88) with ROS1 fusionpositive NSCLC who had not previously received a ROS1 TKI; the median duration of response was 34.1 months (95% CI， 6.8 to 19.6). Ten of the 17 patients (59%; 95% CI， Adrianus Johannes de Langen。
Christoph Springfeld， Matthew G. Krebs，中位无进展生存期为9.0个月（95%CI，这些患者之前接受过一次ROS1 TKI，与长期给药相适应，颅内活性不理想， and median progression-free survival was 9.0 months (95% CI，隶属于美国麻省医学协会， Enriqueta Felip。
25.6至无法估计）。
followed by 160 mg twice daily. Response occurred in 56 of the 71 patients (79%; 95% confidence interval [CI]，洛普替尼是下一代ROS1 TKI，包括那些具有耐药性突变的癌症，2期试验的主要疗效终点是确认的客观缓解；疗效分析包括1期和2期患者， the recommended phase 2 dose of repotrectinib was 160 mg daily for 14 days， 在这项注册的1-2期临床试验中， and 3% discontinued repotrectinib owing to treatment-related adverse events. Conclusions
